Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motavizumab vs Palivizumab for RSV Prophylaxis in High-Risk Children
NCT00129766Phase 3Completed
- Sponsor
- MedImmune
- Start
- Nov 2004
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of motavizumab in respiratory syncytial virus infection (RSV) (2 arms), sponsored by MedImmune. Primary endpoints: Incidence of RSV Hospitalization (Includes Deaths by RSV) and Number of Participants Reporting Any Adverse Events (AEs). Started Nov 2004; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00129766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129766.